As of November 10, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Immunocore Holdings plc. The largest reported stake is Wellington Management Group LLP's, at 11.6%. 15 filings are on record since August 5, 2025 (Schedule 13G/A, August 13, 2026).
Sell to companies like Immunocore Holdings plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Point72 Asset Management, L.P. · Sole voting: 0 · Shared voting: 2,720,043 · Sole dispositive: 0 · Shared dispositive: 2,720,043 · SCHEDULE 13G, 2026-11-09
- · Reporting person: Fmr LLC · Sole voting: 1,732,649 · Shared voting: 0 · Sole dispositive: 1,736,979 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-07
- · Reporting person: Vestal Point Capital, LP · Sole voting: 0 · Shared voting: 1,800,000 · Sole dispositive: 0 · Shared dispositive: 1,800,000 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Wellington Management Group LLP · Sole voting: 0 · Shared voting: 5,803,091 · Sole dispositive: 0 · Shared dispositive: 5,959,773 · SCHEDULE 13G/A, 2026-08-13
- · Holder: Fmr LLC · Percent: 8.8% · SCHEDULE 13G/A
Immunocore Holdings plc has 15 Schedule 13D or 13G filings on record since 2025-08-05. 5 holders' latest filing reports 5% or more of ordinary shares, nominal value 0.002 gbp per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Wellington Management Group LLP | 11.6% | 5,959,773 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| Primecap Management Co | 7.51% | 3,772,234 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Bellevue Group AG | 5.6% | 2,796,803 | SCHEDULE 13G, 2025-11-14 | 2025-08-20 |
| Tang Capital Management, LLC | 5.2% | 2,605,608 | SCHEDULE 13G, 2025-10-24 | 2025-10-17 |
| Point72 Asset Management, L.P. | 5.2% | 2,720,043 | SCHEDULE 13G, 2026-11-09 | 2026-11-06 |
| T. Rowe Price Investment Management, Inc. | 3.7% | 1,891,600 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Fmr LLC | 3.6% | 1,736,979 | SCHEDULE 13G/A, 2026-10-07 | 2026-09-30 |
| Vestal Point Capital, LP | 3.5% | 1,800,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| ELI LILLY & Co | 0% | 0 | SCHEDULE 13G/A, 2025-10-03 | 2025-09-30 |
Holding shares or following this stake? See who's behind Immunocore Holdings plc and the warning signs.
Free to see. No signup.
Keep reading
More on Immunocore Holdings plc and the records around it.
Immunocore Holdings plc elsewhere on the record
Companies that share a holder
- ELI LILLY & Co also filed stake reports on 5 other companies: TRex Bio, Inc. (Oct 2026), Scribe Therapeutics, Inc. (Jul 2026), Ionetix Corp / DE / (Jul 2026)
- Bellevue Group AG also filed stake reports on 6 other companies: Yarrow Bioscience, Inc. (Oct 2026), Jade Biosciences, Inc. (Aug 2026), Celldex Therapeutics, Inc. (May 2026)
- PRIMECAP MANAGEMENT CO/CA/ also filed stake reports on 24 other companies: Xencor Inc (Nov 2026), GRAIL, Inc. (Nov 2026), MARKETAXESS HOLDINGS INC (Nov 2026)
Watch Immunocore Holdings plc
Get an email when Immunocore Holdings plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Immunocore Holdings plc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Immunocore Holdings plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Immunocore Holdings plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Wellington Management Group LLP | 0 | 5,803,091 | 0 | 5,959,773 | SCHEDULE 13G/A, 2026-08-13 |
| Wellington Group Holdings LLP | 0 | 5,803,091 | 0 | 5,959,773 | SCHEDULE 13G/A, 2026-08-13 |
| Wellington Investment Advisors Holdings LLP | 0 | 5,803,091 | 0 | 5,959,773 | SCHEDULE 13G/A, 2026-08-13 |
| Wellington Management Company LLP | 0 | 5,797,517 | 0 | 5,863,698 | SCHEDULE 13G/A, 2026-08-13 |
| Point72 Asset Management, L.P. | 0 | 2,720,043 | 0 | 2,720,043 | SCHEDULE 13G, 2026-11-09 |
| Point72 Capital Advisors, Inc. | 0 | 2,720,043 | 0 | 2,720,043 | SCHEDULE 13G, 2026-11-09 |
| Steven A. Cohen | 0 | 2,720,043 | 0 | 2,720,043 | SCHEDULE 13G, 2026-11-09 |
| Fmr LLC | 1,732,649 | 0 | 1,736,979 | 0 | SCHEDULE 13G/A, 2026-10-07 |
| Abigail P. Johnson | 0 | 0 | 1,736,979 | 0 | SCHEDULE 13G/A, 2026-10-07 |
| Vestal Point Capital, LP | 0 | 1,800,000 | 0 | 1,800,000 | SCHEDULE 13G/A, 2026-08-14 |
| Ryan Wilder | 0 | 1,800,000 | 0 | 1,800,000 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Immunocore Holdings plc by CUSIP 45258D105 and gives its principal executive office as 90 PARK DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE (SCHEDULE 13G, 2026-11-09).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-05 | Wellington Management Group LLP | 9.1% | SCHEDULE 13G/A |
| 2025-08-05 | Wellington Management Group LLP | 10.2% | SCHEDULE 13G/A |
| 2025-08-14 | Primecap Management Co | 7.51% | SCHEDULE 13G/A |
| 2025-10-03 | ELI LILLY & Co | 0% | SCHEDULE 13G/A |
| 2025-10-24 | Tang Capital Management, LLC | 5.2% | SCHEDULE 13G |
| 2025-11-14 | Bellevue Group AG | 5.6% | SCHEDULE 13G |
| 2026-02-17 | T. Rowe Price Investment Management, Inc. | 11.8% | SCHEDULE 13G/A |
| 2026-03-06 | T. Rowe Price Investment Management, Inc. | 6% | SCHEDULE 13G/A |
| 2026-05-15 | Vestal Point Capital, LP | 5.5% | SCHEDULE 13G |
| 2026-05-15 | T. Rowe Price Investment Management, Inc. | 3.7% | SCHEDULE 13G/A |
| 2026-08-06 | Fmr LLC | 8.8% | SCHEDULE 13G/A |
| 2026-08-13 | Wellington Management Group LLP | 11.6% | SCHEDULE 13G/A |
| 2026-08-14 | Vestal Point Capital, LP | 3.5% | SCHEDULE 13G/A |
| 2026-10-07 | Fmr LLC | 3.6% | SCHEDULE 13G/A |
| 2026-11-09 | Point72 Asset Management, L.P. | 5.2% | SCHEDULE 13G |
Questions about who owns Immunocore Holdings plc
Who owns Immunocore Holdings plc?
On this page, 5 holders' latest ownership filings report 5% or more of Immunocore Holdings plc: Wellington Management Group LLP (11.6%, Schedule 13G/A, filed 2026-08-13), Primecap Management Co (7.51%, Schedule 13G/A, filed 2025-08-14), Bellevue Group AG (5.6%, Schedule 13G, filed 2025-11-14), Tang Capital Management, LLC (5.2%, Schedule 13G, filed 2025-10-24) and Point72 Asset Management, L.P. (5.2%, Schedule 13G, filed 2026-11-09).
Who are the largest shareholders of Immunocore Holdings plc?
By the share each holder's latest filing reports, the largest holders of Immunocore Holdings plc on this page are Wellington Management Group LLP (11.6%), Primecap Management Co (7.51%) and Bellevue Group AG (5.6%).
When did Wellington Management Group LLP buy into Immunocore Holdings plc?
The filings give report dates, not purchase dates. The earliest filing from Wellington Management Group LLP on this page is the Schedule 13G/A, filed 2025-08-05, reporting 9.1%; its latest, Schedule 13G/A filed 2026-08-13, reports 11.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 15 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Immunocore Holdings plc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.